People and Business News — 9/22
People News
Clinovo appointed Nandish Poluru as Chief Executive.
Allucent, announced the appointment of Steffany Cox as its chief marketing officer.
Susan Robbins joined HeartcoR Solutions as its director of training. Additionally, Michelle Mills has joined the organization as director of ECG analysis and quality control.
MMS Holdings Inc. announced the appointment of Kelly J. Hill to Chief Strategy Officer.
Florence Healthcare has hired Kristin Surdam, who will lead the company’s thought leadership team and efforts to engage sponsors and contract research organizations, and Gunnar Esiason, who will lead patient-facing strategies.
Elligo Health Research announced Chief Scientific Officer Rebecca Kush, PhD, was recently elected Chair of the Vulcan Advisory Council.
Promontory Therapeutics Inc. announced the appointments of Helene Shea, PhD, as Vice President of Chemistry, Manufacturing and Controls, and Kate Hogg Call as Vice President of Clinical Operations.
Parexel promoted Peyton Howell to the newly created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.
Business News
Strata Oncology, Inc. announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH) trial.
Recognition
Jumo Health announced it has made Inc. Magazine’s Inc. 5000 list.
LaQuinta Jernigan, Chief Operating Officer for mdgroup, has been recognized as one of 100 most inspiring people in life sciences.
WCG’s Vice President, Patient Advocacy and Clinical Research Diversity, Lori Abrams, has been named a Diversity, Equity, and Inclusion Champion.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
